Radiation Treatment in Pathologic N0-N1 Patients Treated with Neoadjuvant Chemotherapy Followed by Surgery for Locally Advanced Breast Canceropen access
- Authors
- Bae, SH[Bae, Sun Hyun]; Park, W[Park, Won]; Huh, SJ[Huh, Seung Jae]; Choi, DH[Choi, Doo Ho]; Nam, SJ[Nam, Seok Jin]; Im, YH[Im, Young-Hyuck]; Ahn, JS[Ahn, Jin Seok]
- Issue Date
- Sep-2012
- Publisher
- KOREAN BREAST CANCER SOC
- Keywords
- Adjuvant radiotherapy; Breast neoplasms; Lymphatic
- Citation
- JOURNAL OF BREAST CANCER, v.15, no.3, pp.329 - 336
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- JOURNAL OF BREAST CANCER
- Volume
- 15
- Number
- 3
- Start Page
- 329
- End Page
- 336
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/64458
- DOI
- 10.4048/jbc.2012.15.3.329
- ISSN
- 1738-6756
- Abstract
- Purpose: This study evaluated the treatment results and the necessity to irradiate the supraclavicular lymph node (SCN) region in pathological N0-N1 (pN0-N1) patients with locally advanced breast cancer treated with neoadjuvant chemotherapy (NAC) followed by surgery and radiotherapy (RT). Methods: Between 1996 and 2008, 184 patients with initial tumor size > 5 cm or clinically positive lymph nodes were treated with NAC followed by surgery and RT. Among these patients, we retrospectively reviewed 98 patients with pN0-N1. Mastectomy was performed in 55%. The pathological lymph node stage was N0 in 49% and N1 in 51%. All patients received adjuvant RT to chest wall or breast and 56 patients (57%) also received RT to the SON region (SCNRT). Results: At 5 years, locoregional recurrence (LRR)-free survival, distant metastasis-free survival, disease-free survival (DFS), and overall survival rates were 93%, 83%, 81%, and 91%, respectively. In pN0 patients, LRR was 7% in SCNRT- group and 5% in SCNRT+ group. In pN1 patients, LRR was 7% in SCNRT- group and 6% in SCNRT+ group. There was no significant difference of LRR, regardless of SCNRT. However, in pN1 patients, there were more patients with poor prognostic factors in the SCNRT+ group compared to SCNRT- group. These factors might be associated with worse DFS in the SCNRT+ group, even though RT was administered to the SON region. Conclusion: Our study showed the similar LRR, regardless of SCNRT in pN0-pN1 breast cancer patients after NAC followed by surgery. Prospective randomized trial is called for to validate the role of SCNAT.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/64458)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.